India’s Drug-Price Agency Rankles Drug Makers
This article was originally published in PharmAsia News
India's drug-pricing regulator is flexing its muscles in going after drug makers for allegedly charging more for their products than rules allow. The National Pharmaceutical Pricing Authority has been going after drug makers even as the two entities are involved in court litigation over the price limits. The fight between the two entities over price caps has led to a stack of court cases, partly because of a concern of a conflict between regulations and policy. But the chief problem may be a lack of coordination between the NPPA and the country's regulator of quality, the Drug Controller General of India. (Click here for more
You may also be interested in...
Complaint lists host of problems with implementation of the rule that allows states to sponsor programs to import certain prescription drugs from Canada; at least six states have enacted legislation to sponsor these programs.
Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.